糖肽抗生素市場：按藥物、按疾病適應症、按分銷渠道、按地區 - 規模、份額、展望、機會分析，2022-2030 年

Glycopeptide Antibiotics Market, by Drug, by Disease Indication, by Distribution channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2023年01月02日 | 出版商:

Coherent Market Insights | 英文 154 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

糖肽類抗生素是一類通過抑制肽聚醣合成來抑制細菌細胞壁形成的抗生素。糖肽類抗生素用於治療腹瀉、心內膜炎、艱難梭菌感染引起的腸炎、住院期間或使用呼吸機期間發生的肺炎以及嚴重的皮膚和皮膚結構感染。引起傳染病的細菌大致分為兩種類型：沒有覆蓋細胞壁的外膜的革蘭氏陽性菌，以及具有覆蓋細胞壁的額外膜的革蘭氏陰性菌。革蘭氏陰性菌對糖肽具有耐藥性，因為它們有一層外膜可以防止糖肽進入細胞壁，儘管糖肽對革蘭氏陽性菌的感染有效。

此外，一些糖肽可用於嚴重感染的靜脈內給藥和輕度感染的口服給藥。糖肽類抗生素 (GPA) 通常用於治療由金黃色葡萄球菌、腸球菌和艱難梭菌等多重耐藥革蘭氏陽性菌引起的危及生命的感染。首先從植物和土壤細菌中分離出一個抗生素家族，其結構包含糖基化環狀或多環非核醣體肽。通過乾擾肽聚醣的產生，這些抗生素會干擾易感生物（主要是革蘭氏陽性球菌）的細胞壁組裝。萬古黴素、替考拉寧和雷莫拉寧是第一代糖肽類抗生素的例子。第二代半合成糖肽類抗生素包括奧利萬星、達巴萬星和特拉萬星。

市場動態

糖肽類抗生素產品發佈和批准的增加預計將在預測期內推動市場增長。例如，2019 年 6 月，生物製藥公司 ANI Pharmaceuticals, Inc. 獲得了美國 FDA 批准的鹽酸萬古黴素口服 USP 250mg/5ml 補充劑，用於治療各種感染。

這項研究的主要特點

本報告詳細分析了以 2021 年為基準年的預測期 (2022-2030) 的全球糖肽類抗生素市場、市場規模（百萬美元）和復合年增長率 (CAGR%)。
解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
它還提供有關市場促進因素、抑制因素、機會、新產品發佈或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
根據以下參數介紹全球糖肽抗生素市場的主要參與者 - 公司亮點、產品組合、主要亮點、財務業績和戰略。
本研究涵蓋的主要公司包括 ANI Pharmaceuticals, Inc.、Fresenius SE & Co. KGaA、Pfizer Inc.、Mylan N.V.、Novartis AG、Hikma Pharmaceuticals plc、Aurobindo Pharma、AbbVie Inc.、Melinta Therapeutics, Inc 、Cumberland Pharmaceuticals Inc.、Theravance Biopharma、Janssen Global Services, LLC、Bristol-Myers Squibb Company 和 GlaxoSmithKline plc。
這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發佈、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
《全球糖肽抗生素市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以通過用於分析全球糖肽抗生素市場的各種戰略矩陣來促進決策制定。

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
德國
英國
法國
意大利
西班牙
俄羅斯
其他歐洲地區
亞太地區
中國
印度
日本
澳大利亞
韓國
東盟
其他亞太地區
中東
海灣合作委員會
以色列
其他中東地區
非洲
南非
中非
北非

第 9 章競爭格局

競爭快照
- Competitive Snapshot
  - ANI Pharmaceuticals, Inc.
- Fresenius SE & Co. KGaA
- Pfizer Inc
- Mylan N.V.
- Novartis AG
- Hikma Pharmaceuticals plc
- Aurobindo Pharma
- AbbVie Inc.
- Melinta Therapeutics, Inc
- Cumberland Pharmaceuticals Inc
- Theravance Biopharma
- Janssen Global Services, LLC
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
第 10 章
- 參考文獻
- 調查方法

簡介目錄

Product Code: CMI5455

Glycopeptide antibiotics are the type of antibiotics that inhibit bacterial cell wall formation by inhibiting peptidoglycan synthesis. Glycopeptide antibiotics are used for the treatment of Clostridium difficile-associated diarrhea, endocarditis, enterocolitis Pneumonia acquired during a hospital stay or that develops while using a ventilator, and severe skin and skin structure infections. Gram-positive bacteria, which do not have an outer membrane covering their cell walls, and gram-negative bacteria, which have an additional membrane covering the cell walls, are the two main types of bacteria that cause infections. Gram-negative bacteria are resistant to glycopeptides because they have an outer membrane that prevents the entry of glycopeptides into their cell wall, although glycopeptides are effective against gram-positive bacterial infections.

Moreover, some glycoproteins are administered through the intravenous route in severe infection and oral treatment is used at the time of mild infection. Life-threatening infections brought on by multidrug-resistant Gram-positive organisms like Staphylococcus aureus, Enterococcus species, and Clostridium difficile are routinely treated using glycopeptide antibiotics (GPAs). One of a group of antibiotics has structures that contain either a glycosylated cyclic or polycyclic nonribosomal peptide that was first isolated from plant and soil bacteria. By preventing the manufacture of peptidoglycan, these antibiotics interfere with the cell wall construction of organisms that are sensitive (mostly Gram-positive cocci). Vancomycin, teicoplanin, and ramoplanin are examples of first-generation glycopeptide antibiotics. Oritavancin, dalbavancin, and telavancin are examples of second-generation semi-synthetic glycopeptide antibiotics.

Market Dynamics

Increasing product launch and approval of glycopeptide antibiotics are expected to drive the market growth over the forecast period. For instance, in June 2019, ANI Pharmaceuticals, Inc., a biopharmaceutical company received the U.S. FDA prior approval supplement for its Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml for the treatment of various infections.

Key features of the study:

This report provides an in-depth analysis of the global glycopeptide antibiotics market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global glycopeptide antibiotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global glycopeptide antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global glycopeptide antibiotics market

Detailed Segmentation:

Global Glycopeptide Antibiotics Market, By Drug:
- Vancocin
- Orbactiv
- Dalvance
- Kimyrsa
- Others
Global Glycopeptide Antibiotics Market, By Disease Indication:
- Clostridium difficile-associated Diarrhea
- Endocarditis
- Skin Structure Infections
- Others
Global Glycopeptide Antibiotics Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Glycopeptide Antibiotics Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest Of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- ANI Pharmaceuticals, Inc.*
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Fresenius SE & Co. KGaA
- Pfizer Inc
- Mylan N.V.
- Novartis AG
- Hikma Pharmaceuticals plc
- Aurobindo Pharma
- AbbVie Inc.
- Melinta Therapeutics, Inc
- Cumberland Pharmaceuticals Inc
- Theravance Biopharma
- Janssen Global Services, LLC
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Key Development Strategies
Mergers And Acquisition Scenario
Market Trends
Brand Analysis
Regulatory Scenario
PEST Analysis
Pricing Analysis

4. Global Glycopeptide Antibiotics Market - Impact of Coronavirus (Covid-19) Pandemic

COVID-19 Epidemiology
Impact on Manufacturing
Impact on Manufacturing

5. Global Glycopeptide Antibiotics Market, By Drug, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Vancocin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Orbactiv
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Dalvance
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Kimyrsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global Glycopeptide Antibiotics Market, By Disease Indication, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Clostridium difficile-associated Diarrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Endocarditis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Skin Structure Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global Glycopeptide Antibiotics Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

8. Global Glycopeptide Antibiotics Market, By Region, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
North America
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030, (US$ Mn)
South Africa
Central Africa
North Africa

9. Competitive Landscape

Competitive Snapshot
- ANI Pharmaceuticals, Inc.*
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Fresenius SE & Co. KGaA
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Pfizer Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Mylan N.V.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Novartis AG
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Hikma Pharmaceuticals plc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Aurobindo Pharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
AbbVie Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Melinta Therapeutics, Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Cumberland Pharmaceuticals Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Theravance Biopharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Janssen Global Services, LLC
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Bristol-Myers Squibb Company
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
GlaxoSmithKline plc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies